drugset / Trial / NCT07548853

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

NCT07548853

Phase 3 Recruiting 30 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis

Timeline

Start
2026-05-13
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications